Hormonal Contraception and HIV Risk: Understanding the ECHO Trial

Can we help you find something?
Advocacy & Awareness
Beyond 2020
Contraceptive Security
ECHO Study
FP in Humanitarian Settings
Financing
Innovation
Policy and Enabling Environment
Rights
Service Delivery & Quality
Young People
Commitment Maker
Country
Commitment Maker
Country
Hormonal Contraception and HIV Risk: Understanding the ECHO Trial
Publication Date: 04/03/2019

The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study is an open-label, randomized, clinical trial comparing three highly effective, reversible methods of contraception — the progestogen-only injectable depot-medroxyprogesterone acetate (DMPA), a levonorgestrel implant, and the non-hormonal copper intrauterine device — to evaluate whether there is any difference in the risk of acquiring HIV infection among users of these methods. Results, expected in mid-2019, will help guide the implementation of safe, effective policies and services that will enable women at high risk of HIV to make fully informed choices about contraception and HIV prevention.

Tags
Topics :
Source:
FP2020